Cargando…
VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma
BACKGROUND: Vascular endothelial growth factor (VEGF) isoforms, particularly the diffusible VEGF-121, could play a major role in the response of recurrent glioblastoma (GB) to anti-angiogenetic treatment with bevacizumab. We hypothesized that circulating VEGF-121 may reduce the amount of bevacizumab...
Autores principales: | Martini, Maurizio, de Pascalis, Ivana, D’Alessandris, Quintino Giorgio, Fiorentino, Vincenzo, Pierconti, Francesco, Marei, Hany El-Sayed, Ricci-Vitiani, Lucia, Pallini, Roberto, Larocca, Luigi Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5946426/ https://www.ncbi.nlm.nih.gov/pubmed/29747600 http://dx.doi.org/10.1186/s12885-018-4442-2 |
Ejemplares similares
-
Inhibition of autophagy increases susceptibility of glioblastoma stem cells to temozolomide by igniting ferroptosis
por: Buccarelli, Mariachiara, et al.
Publicado: (2018) -
Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcome
por: Cesarini, Valeriana, et al.
Publicado: (2017) -
Glioblastoma endothelium drives bevacizumab‐induced infiltrative growth via modulation of PLXDC1
por: Falchetti, Maria Laura, et al.
Publicado: (2018) -
Brain Invasion along Perivascular Spaces by Glioma Cells: Relationship with Blood–Brain Barrier
por: Pacioni, Simone, et al.
Publicado: (2019) -
Dilation of Brain Veins and Perivascular Infiltration by Glioblastoma Cells in an In Vivo Assay of Early Tumor Angiogenesis
por: D'Alessandris, Quintino Giorgio, et al.
Publicado: (2021)